Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gülten Korkmaz

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|January 27, 2015
Rate of blood pressure control and antihypertensive treatment approaches in diabetic patients with hypertensionNihan Kahya Eren, Ece Harman, Devrim Dolek, et al.
International Journal of Endocrinology|May 18, 2026
Clinical Associations of Osteoporosis in BCR::ABL1 Negative Myeloproliferative NeoplasmsMürüvvet Seda Aydin, Simten Dagdas, Mehmet Sezgin Pepeler, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|May 27, 2022
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of <i>BCR::ABL1</i> IS Transcript LevelsFunda Ceran, Sema Akıncı, Mehmet Ali Uçar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2024
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid LeukemiaMehmet Sezgin Pepeler, Mesut Tıglıoglu, Simten Dagdas, et al.
Leukemia Research|April 10, 2024
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experienceSüreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, et al.
Viruses|July 29, 2023
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVacÇiğdem Erol, Zeynep Ece Kuloğlu, Bircan Kayaaslan, et al.
Leukemia Research|May 6, 2026
Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature reviewDeniz Özmen, Derya Deniz Kürekçi, Vildan Özkocaman, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir|January 27, 2015
Rate of blood pressure control and antihypertensive treatment approaches in diabetic patients with hypertensionNihan Kahya Eren, Ece Harman, Devrim Dolek, et al.
International Journal of Endocrinology|May 18, 2026
Clinical Associations of Osteoporosis in BCR::ABL1 Negative Myeloproliferative NeoplasmsMürüvvet Seda Aydin, Simten Dagdas, Mehmet Sezgin Pepeler, et al.
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|May 27, 2022
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of <i>BCR::ABL1</i> IS Transcript LevelsFunda Ceran, Sema Akıncı, Mehmet Ali Uçar, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 11, 2024
Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid LeukemiaMehmet Sezgin Pepeler, Mesut Tıglıoglu, Simten Dagdas, et al.
Leukemia Research|April 10, 2024
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experienceSüreyya Yiğit Kaya, Yaşa Gül Mutlu, Ümit Yavuz Malkan, et al.
Viruses|July 29, 2023
BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVacÇiğdem Erol, Zeynep Ece Kuloğlu, Bircan Kayaaslan, et al.
Leukemia Research|May 6, 2026
Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature reviewDeniz Özmen, Derya Deniz Kürekçi, Vildan Özkocaman, et al.
Pageof 1